Advances in Diabetes and Metabolism(CEASE PUBLICATION) Vol. 1(1), pp. 16 - 20
DOI: 10.13189/adm.2013.010104
Reprint (PDF) (148Kb)

Mipomersen: Pharmacology, Clinical Trials and Its Potential Role in Therapy

Jeffery Evans^*, Dorothy Ann Shelton
University of Louisiana at Monroe College of Pharmacy

ABSTRACT

Mipomersen is a novel pharmacologic agent that utilizes anti-sense technology to reduce LDL in patients with very high LDL. The medication has been approved in the United States based on a series of small trials proving efficacy even with when added to traditional therapy. Safety concerns have been raised due to a potential for liver toxicity.

KEYWORDS
Mipomersen, Anti-sense, Hyperlipidemia, Lipids

Cite This Paper in IEEE or APA Citation Styles
(a). IEEE Format:
[1] Jeffery Evans , Dorothy Ann Shelton , "Mipomersen: Pharmacology, Clinical Trials and Its Potential Role in Therapy," Advances in Diabetes and Metabolism(CEASE PUBLICATION), Vol. 1, No. 1, pp. 16 - 20, 2013. DOI: 10.13189/adm.2013.010104.

(b). APA Format:
Jeffery Evans , Dorothy Ann Shelton (2013). Mipomersen: Pharmacology, Clinical Trials and Its Potential Role in Therapy. Advances in Diabetes and Metabolism(CEASE PUBLICATION), 1(1), 16 - 20. DOI: 10.13189/adm.2013.010104.